38 results about "AXL Protein" patented technology

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The invention discloses application of a regent for detecting Axl receptor tyrosine kinase to prepare a kit for detecting whether a pregnant woman has a premature rupture of membranes. The regent is a monoclonal antibody of the Axl receptor tyrosine kinase which is labeled by biotin. The kit includes a perforated plate coated with the monoclonal antibody of the Axl receptor tyrosine kinase, biotin-labeled monoclonal antibody detection liquid of the Axl receptor tyrosine kinase, avidin-horse radish peroxidase combined with biotin-labeled monoclonal antibody of the Axl receptor tyrosine kinase, a chromogenic substrate 3',3',5,5'-tetramethylbenzidine, and an Axl protein standard substance. A preparation method for the kit comprises the following steps of: (1) preparing the perforated plate coated with the monoclonal antibody of the Axl receptor tyrosine kinase; (2) preparing the biotin-labeled monoclonal antibody detection liquid of the Axl receptor tyrosine kinase; and (3) preparing avidin-horse radish peroxidase, the chromogenic substrate 3',3',5,5'-tetramethylbenzidine, and the protein standard substance of the Axl receptor tyrosine kinase.

The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natural killer cell comprising treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3L to differentiate into precursor natural killer cell, and treating the resulting precursor natural killer cell with ligand of AxI receptor tyrosine kinase to produce mature natural killer cell.

The invention discloses a monoclonal antibody specially combined with AXL or an antigen combined segment thereof. The monoclonal antibody can be specifically combined with an AXL protein. The antibodydisclosed by the invention can be used for preventing and treating diseases induced by overexpression of the AXL protein, and has a wide application prospect clinically.

Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.

Compositions and methods are provided for treating a human metastatic cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.

Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.

The invention provides an antibody targeting AXL protein or an antigen binding fragment thereof, a preparation method and application thereof. The invention also provides isolated polynucleotides encoding the antibodies or antigen binding fragments thereof, and vectors comprising the isolated polynucleotides. The AXL-targeting antibody provided by the invention can be combined with AXL protein with high affinity, can mediate ADCC to kill tumors, or can be used as a target recognition domain of CART cells to play an anti-tumor role, can be used for preventing or treating tumors, and has a wide application prospect.

Peptides from the tyrosine-protein kinase receptor UFO protein (AXL) are provided that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample and the AXL protein is quantitated in the Liquid Tissue sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.

Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.